This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Torrero, M. N. Articles by Li, S. Search for Related Content PubMed PubMed Citation Articles by Torrero, M. N. Articles by Li, S.

Stat1 Deficiency in the Host Enhances Interleukin-12–Mediated Tumor Regression

¹ Department of Comparative Biomedical Sciences, Louisiana State University, Baton Rouge, Louisiana and ² Department of Biostatistics and Preventive Medicine, Vanderbilt University Medical Center, Nashville, Tennessee

Requests for reprints: Shulin Li, Department of Comparative Biomedical Sciences, Louisiana State University, Skip Bertman Drive, Baton Rouge, LA 70803. Phone: 22-5578-9032; Fax: 22-5578-9895; E-mail: sli{at}vetmed.lsu.edu.

Signal transducer and activator of transcription 1 (Stat1) is considered a key transcription factor that inhibits tumorigenesis, and Stat1 activation in the host is required for interleukin-12 (IL-12)–mediated generation of CTL activity. Using syngeneic Stat1–/– C3H mice bearing SCCVII tumors in this study, we discovered opposite results. Stat1 deficiency in the host significantly enhances IL-12–mediated tumor regression, resulting in tumor eradication from 60% of SCCVII tumor–bearing mice and significant inhibition of tumor growth when compared with control treatment (P < 0.01). This effect is independent of both Stat1-activating cytokine IFN- and Stat1-downstream effector molecule FasL because neither neutralization of IFN- nor knocking out of FasL enhances or inhibits IL-12–mediated tumor regression. IL-12 induces a high intensity of tumor-specific CTL activity in Stat1-deficient mice (P < 0.01), increases the CD8 T-cell density in tumor bearing Stat1–/– mice, and induces a T-cell–dependent tumor regression. The increased CTL activity and the high-intensity infiltration of T cells into the tumors in IL-12–treated Stat1–/– mice are likely due to the longer survival than the same cells from wild-type mice. Together, the data show that inhibition of Stat1 expression in the host enhances tumor-local IL-12 gene therapy for regressing tumors. This conclusion provides a new concept for designing an effective treatment strategy. (Cancer Res 2006; 66(8): 4461-7)

This article has been cited by other articles:

				S. Zhu, M. Waguespack, S. A. Barker, and S. Li Doxorubicin Directs the Accumulation of Interleukin-12 Induced IFN{gamma} into Tumors for Enhancing STAT1 Dependent Antitumor Effect Clin. Cancer Res., July 15, 2007; 13(14): 4252 - 4260. [Abstract] [Full Text] [PDF]

				V. W. Y. Lui, A. L. Boehm, P. Koppikar, R. J. Leeman, D. Johnson, M. Ogagan, E. Childs, M. Freilino, and J. R. Grandis Antiproliferative Mechanisms of a Transcription Factor Decoy Targeting Signal Transducer and Activator of Transcription (STAT) 3: The Role of STAT1 Mol. Pharmacol., May 1, 2007; 71(5): 1435 - 1443. [Abstract] [Full Text] [PDF]